Sialic acid-modified dexamethasone lipid calcium phosphate gel core nanoparticles for target treatment of kidney injury

Liu, Hongbing; Zhang, Hui; Yin, Na; Zhang, Ying; Gou, Jingxin; Yin, Tian; He, Haibing; Ding, Hong; Tang, Xing

doi:10.1039/d0bm00581a

Cited by 21 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Produce pro-inflammatory cytokines/chemokines and interact with immune cells; 3. Apoptosis and necrosis; E-selectin Sialic acid [ 161 ] P-selectin Fucoidan [ 162 ] ICAM-1 ITGα L β 2 [ 151 ] Macrophages 1. Produce excess RONS; 2.…”

Section: Advantages Of Nanodrugs In Aki Treatmentmentioning

confidence: 99%

“…At present, nano- anti -inflammatory drugs in AKI treatment are mainly divided into two categories: First, nanocarriers loaded with anti-inflammatory drugs (e.g., TLR9 antagonist [ 153 ], immune modulator glucocorticoid [ 161 ], and anti-TNF-α [ 225 ]) for improved renal targeting and therapeutic effects. Second, mesenchymal stem cell (MSC)-derived exosomes with intrinsic renal targeting and anti-inflammatory effects were also adopted for AKI treatment [ 151 , 152 , 226 , 227 ].…”

Section: Nanocarriers For Antioxidants and Anti-inflammatory Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney

Chen

Nan

Yang

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

Section: Advantages Of Nanodrugs In Aki Treatmentmentioning

confidence: 99%

Section: Nanocarriers For Antioxidants and Anti-inflammatory Drugsmentioning

confidence: 99%

Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney

Chen

Nan

Yang

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

“…Regarding the kidneys, the size and charge of LNPs considerably influences delivery efficiency (e.g., small LNPs penetrate more easily into the kidneys but are more easily eliminated) [194,195]. Although further research is needed to increase the efficiency and specificity of LNPs for the kidney, these systems have been successfully used in several studies for drug delivery to the kidney [196][197][198][199].…”

Section: Immune System Against Gene Editingmentioning

confidence: 99%

Genetic Kidney Diseases (GKDs) Modeling Using Genome Editing Technologies

Gómez-García

Martínez-Pulleiro

Carrera

et al. 2022

Cells

View full text Add to dashboard Cite

Genetic kidney diseases (GKDs) are a group of rare diseases, affecting approximately about 60 to 80 per 100,000 individuals, for which there is currently no treatment that can cure them (in many cases). GKDs usually leads to early-onset chronic kidney disease, which results in patients having to undergo dialysis or kidney transplant. Here, we briefly describe genetic causes and phenotypic effects of six GKDs representative of different ranges of prevalence and renal involvement (ciliopathy, glomerulopathy, and tubulopathy). One of the shared characteristics of GKDs is that most of them are monogenic. This characteristic makes it possible to use site-specific nuclease systems to edit the genes that cause GKDs and generate in vitro and in vivo models that reflect the genetic abnormalities of GKDs. We describe and compare these site-specific nuclease systems (zinc finger nucleases (ZFNs), transcription activator-like effect nucleases (TALENs) and regularly clustered short palindromic repeat-associated protein (CRISPR-Cas9)) and review how these systems have allowed the generation of cellular and animal GKDs models and how they have contributed to shed light on many still unknown fields in GKDs. We also indicate the main obstacles limiting the application of these systems in a more efficient way. The information provided here will be useful to gain an accurate understanding of the technological advances in the field of genome editing for GKDs, as well as to serve as a guide for the selection of both the genome editing tool and the gene delivery method most suitable for the successful development of GKDs models.

show abstract

“…2 Renal IRI remains the major cause of acute kidney injury (AKI). 3 Clinically, AKI is a common disease with high morbidity and mortality rates afflicting a large population worldwide. 4 Current treatment options for AKI mainly include appropriate fluid control, nutritional support, and renal replacement, emphasizing early prevention, early treatment, and individualized treatment for different causes and conditions.…”

Section: Introductionmentioning

confidence: 99%

An Albumin-Enriched Nanocomplex Achieves Systemic Delivery of Clopidogrel Bisulfate to Ameliorate Renal Ischemia Reperfusion Injury in Rats

Luo

et al. 2022

Mol. Pharmaceutics

View full text Add to dashboard Cite

Herein, an albumin-enriched nanocomplex was developed for the solubilization and intravascular administration of clopidogrel bisulfate (CLP). In particular, CLP nanoparticles (HS-CLP-NPs) were synthesized via an improved nab-technology method using Solutol HS-15, and bovine serum albumin (BSA) was further enriched on the nanoparticle surface forming a protein corona (BH-CLP-NPs). BH-CLP-NPs displayed an average size of 163.4 ± 10.5 nm, a zeta potential of 1.85 ± 0.03 mV, an encapsulation efficiency of 99.9%, and a drug loading capacity of 32.9%. The cumulative release of CLP from BH-CLP-NPs reached about 60% within 168 h. The pharmacokinetic study on the CLP metabolite indicated that the BSAenriched nanoparticle showed greater in vivo exposure. Pharmacodynamic studies in the renal ischemia/reperfusion injury rat model further demonstrated the renal protective effect of systemically administered BH-CLP-NPs against acute kidney injury with significantly downregulated blood urea nitrogen and creatinine levels. Overall, the albumin-enriched nanocomplexes offer a neat and efficient strategy for the development of poorly water-soluble drugs to achieve intravascular administration.

show abstract

Sialic acid-modified dexamethasone lipid calcium phosphate gel core nanoparticles for target treatment of kidney injury

Abstract: SA-NPs were constructed to target the treatment of AKI and improve therapeutic efficiency and reduce side effects.

Cited by 21 publications

References 36 publications

Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney

Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney

Genetic Kidney Diseases (GKDs) Modeling Using Genome Editing Technologies

An Albumin-Enriched Nanocomplex Achieves Systemic Delivery of Clopidogrel Bisulfate to Ameliorate Renal Ischemia Reperfusion Injury in Rats

Contact Info

Product

Resources

About